

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24 NOV 20 CA/CAplus patent kind codes will be updated
NEWS 25 DEC 01 CAS REGISTRY updated with new ambiguity codes

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:56:33 ON 01 DEC 2006

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:56:48 ON 01 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7
DICTIONARY FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.



TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\10510609.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

ring bonds :

Ring Bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-12 7-8 8-9 8-14 8-10 10-11 11-12 11-13

1 2

13-14 exact/norm bonds


exact_norm_bonds ?

normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
 SAMPLE SEARCH INITIATED 16:57:07 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 33256 TO ITERATE

6.0% PROCESSED 2000 ITERATIONS 2 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 654220 TO 676020
 PROJECTED ANSWERS: 319 TO 1011

L2 2 SEA SSS SAM L1

=> s 11 ful
 FULL SEARCH INITIATED 16:57:12 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 667611 TO ITERATE

100.0% PROCESSED 667611 ITERATIONS 381 ANSWERS
 SEARCH TIME: 00.00.03

L3 381 SEA SSS FUL L1

	SINCE FILE ENTRY	TOTAL SESSION
=> file caplus		
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	166.94	167.15

10510609

FILE 'CAPLUS' ENTERED AT 16:57:19 ON 01 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 37 L3

=> file registry			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	0.46	167.61	

FILE 'REGISTRY' ENTERED AT 16:58:04 ON 01 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7
DICTIONARY FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10510609.str

10510609



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-12 7-8 8-9 8-14 9-10 10-11 11-12 11-13

13-14

exact/norm bonds :

5-7 6-12 7-8 8-9 8-14 9-10 10-11 11-12 11-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 16:58:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1168 TO ITERATE

100.0% PROCESSED 1168 ITERATIONS
SEARCH TIME: 00.00.01

9 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 21310 TO 25410
PROJECTED ANSWERS: 9 TO 360

10510609

L6 9 SEA SSS SAM L5

=> s 15 ful
 FULL SEARCH INITIATED 16:58:30 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 23289 TO ITERATE

100.0% PROCESSED 23289 ITERATIONS 272 ANSWERS
 SEARCH TIME: 00.00.01

L7 272 SEA SSS FUL L5

=> file caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 166.94 334.55

FILE 'CAPLUS' ENTERED AT 16:58:33 ON 01 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2006 VOL 145 ISS 24
 FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17
 L8 6 L7

=> d abs bib hitstr 1-6

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 GI



$$Q = -(CR^1)_2 n - X - (CR^1)_2 p - V - (R^2)_q$$

AB The present invention relates to benzazocine compds. [I; wherein R1a = H, (un)substituted C1-6 alkyl, OR4; R1b = H, (un)substituted C1-6 alkyl; X = a bond, CO, O, NR4; R1 = H, halo, OR4, NO2, S(O)mR4, cyano, each (un)substituted C1-10 alkyl, aryl, C2-6 alkenyl, C3-10 cycloalkyl, alkynyl, or heterocyclyl, COR4, CO2R4, CON(R4)2, S(O)mN(R4)2, N(R4)2; V = H, CF3, aryl, heterocyclyl, C3-10 cycloalkyl; R2 = H, (un)substituted C1-10 alkyl, (CR1b)tOR4, halo, cyano, NO2, CF3, (CR1b)tN(R4)2, CO2R4, COR4, SO2R4, (CR1b)tNR4(CR1b)tr5, (CR1b)tS(O)mNR4, CO2R4, NR4COR4, each (un)substituted aryl or heterocyclyl; R4 = H, each (un)substituted C1-10 alkyl, C3-10 cycloalkyl, aryl, or heterocyclyl, CF3; R5 = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n, p, p1, q, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase, in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.

AN 2003:836849 CAPLUS

DN 139:337990

TI Preparation of 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[a] [8]annulene derivatives as tyrosine kinase inhibitors

IN Kim, Annette; Stump, Craig A.; Dinsmore, Christopher J.; Graham, Samuel L.; Williams, Theresa M.; Nguyen, Diem N.; Trotter, B. Wesley

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.


PI	WO 2003086395	A1	20031023	WO 2003-US10737	20030408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2480879	AA	20031023	CA 2003-2480879	20030408
AU	2003230835	A1	20031027	AU 2003-230835	20030408

EP 1496897 A1 20050119 EP 2003-723935 20030408
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005528392 T2 20050922 JP 2003-583414 20030408
 US 2005239815 A1 20051027 US 2004-510611 20041008
 PRAI US 2002-372644P P 20020412
 WO 2003-US10737 W 20030408
 OS MARPAT 139:337990
 IT 83090-52-2P 129177-71-5P 129177-90-8P
 616888-01-8P 616888-02-9P 616888-07-4P
 616888-09-6P 616888-10-9P 616888-11-0P
 616888-12-1P 616888-13-2P 616888-15-4P
 616888-16-5P 616888-17-6P 616888-18-7P
 616888-19-8P 616888-20-1P 616888-21-2P
 616888-25-6P 616888-27-8P 616888-28-9P
 616888-29-0P 616888-35-8P 616888-37-0P
 616888-38-1P 616888-39-2P 616888-45-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of hexahydro(epiminomethano)benzo[a][8]annulene
 derivs. as tyrosine kinase inhibitors for treatment of receptor type
 tyrosine kinase-related diseases)
 RN 83090-52-2 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 129177-71-5 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro- (9CI) (CA INDEX
 NAME)




RN 129177-90-8 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 616888-01-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616888-02-9 CAPLUS


CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 616888-07-4 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 616888-09-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 616888-10-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-10-nitro- (9CI) (CA INDEX NAME)



RN 616888-11-0 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-10-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 616888-12-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 616888-13-2 CAPLUS


CN 2,5-Ethano-3-benzazocine, 8,9-dibromo-1,2,3,4,5,6-hexahydro- (9CI) (CA

INDEX NAME)




RN 616888-15-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 8,9-dibromo-1,2,3,4,5,6-hexahydro-10-nitro- (9CI) (CA INDEX NAME)




RN 616888-16-5 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




RN 616888-17-6 CAPLUS

CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 10-amino-1,4,5,6-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 616888-18-7 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 1,2,3,4,5,6-hexahydro-, dihydrobromide (9CI) (CA INDEX NAME)




● 2 HBr

RN 616888-19-8 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-10-[(trifluoroacetyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 616888-20-1 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-(1,2,3,4,5,6-hexahydro-2,5-ethano-3-benzazocin-10-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 616888-21-2 CAPLUS
 CN Acetamide, N-[3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-2,5-ethano-3-benzazocin-10-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 616888-25-6 CAPLUS


CN Benzaldehyde, 2-bromo-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 616888-27-8 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-nitro- (9CI) (CA INDEX NAME)




RN 616888-28-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-nitro- (9CI) (CA INDEX NAME)



RN 616888-29-0 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-9-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 616888-35-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-phenyl-3-[2-(1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 616888-37-0 CAPLUS

CN Benzaldehyde, 4-[(1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl)methyl]- (9CI) (CA INDEX NAME)



RN 616888-38-1 CAPLUS

CN Benzonitrile, 4-[(1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 616888-39-2 CAPLUS

CN Benzoic acid, 2-bromo-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 616887-86-6
CMF C21 H22 Br N O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 616888-45-0 CAPLUS
 CN Benzoic acid, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 616887-00-4P 616887-17-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of hexahydro(epiminomethano)benzo[a] [8]annulene derivs. as tyrosine kinase inhibitors for treatment of receptor type tyrosine kinase-related diseases)

RN 616887-00-4 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-


10-nitro- (9CI) (CA INDEX NAME)



RN 616887-17-3 CAPLUS

CN Benzonitrile, 2-bromo-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-ylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 83090-43-1P 83090-63-5P 83090-64-6P
 83090-65-7P 616886-60-3P 616886-61-4P
 616886-62-5P 616886-63-6P 616886-64-7P
 616886-65-8P 616886-66-9P 616886-67-0P
 616886-68-1P 616886-69-2P 616886-70-5P
 616886-71-6P 616886-72-7P 616886-73-8P
 616886-74-9P 616886-75-0P 616886-76-1P
 616886-77-2P 616886-78-3P 616886-79-4P
 616886-80-7P 616886-81-8P 616886-82-9P
 616886-83-0P 616886-84-1P 616886-85-2P
 616886-86-3P 616886-87-4P 616886-88-5P
 616886-89-6P 616886-90-9P 616886-91-0P
 616886-92-1P 616886-93-2P 616886-94-3P
 616886-95-4P 616886-96-5P 616886-97-6P
 616886-98-7P 616886-99-8P 616887-01-5P
 616887-02-6P 616887-03-7P 616887-04-8P
 616887-05-9P 616887-06-0P 616887-07-1P
 616887-08-2P 616887-09-3P 616887-10-6P
 616887-11-7P 616887-12-8P 616887-13-9P
 616887-14-0P 616887-15-1P 616887-16-2P
 616887-18-4P 616887-19-5P 616887-20-8P
 616887-21-9P 616887-22-0P 616887-23-1P
 616887-24-2P 616887-25-3P 616887-26-4P
 616887-27-5P 616887-28-6P 616887-29-7P
 616887-30-0P 616887-31-1P 616887-32-2P
 616887-33-3P 616887-34-4P 616887-35-5P
 616887-36-6P 616887-37-7P 616887-38-8P
 616887-39-9P 616887-40-2P 616887-41-3P
 616887-42-4P 616887-43-5P 616887-44-6P
 616887-45-7P 616887-46-8P 616887-47-9P
 616887-48-0P 616887-49-1P 616887-50-4P


616887-51-5P 616887-52-6P 616887-53-7P
 616887-54-8P 616887-55-9P 616887-56-0P
 616887-57-1P 616887-58-2P 616887-59-3P
 616887-60-6P 616887-61-7P 616887-62-8P
 616887-63-9P 616887-64-0P 616887-65-1P
 616887-66-2P 616887-67-3P 616887-68-4P
 616887-69-5P 616887-70-8P 616887-71-9P
 616887-72-0P 616887-73-1P 616887-74-2P
 616887-75-3P 616887-76-4P 616887-77-5P
 616887-78-6P 616887-79-7P 616887-80-0P
 616887-81-1P 616887-82-2P 616887-83-3P
 616887-84-4P 616887-85-5P 616887-86-6P
 616887-87-7P 616887-88-8P 616887-89-9P
 616887-90-2P 616887-91-3P 616887-92-4P
 616887-93-5P 616887-94-6P 616887-95-7P
 616887-96-8P 616887-97-9P 616887-99-1P
 616888-00-7P 616888-03-0P 616888-04-1P
 616888-14-3P 616888-22-3P 616888-23-4P
 616888-46-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hexahydro(epiminomethano)benzo[a][8]annulene derivs. as tyrosine kinase inhibitors for treatment of receptor type tyrosine kinase-related diseases)


RN 83090-43-1 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 83090-63-5 CAPLUS

CN 2,5-Ethano-3-benzazocin-8-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




RN 83090-64-6 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 83090-65-7 CAPLUS


CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 616886-60-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-61-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-2-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-62-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-63-6 CAPLUS


CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-6-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616886-64-7 CAPLUS


CN 2,5-Ethano-3-benzazocin-10-amine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (9CI) (CA INDEX NAME)



RN 616886-65-8 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-66-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-naphthalenylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-67-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-7-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-68-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(3-methylphenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-69-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(4-bromo-1H-pyrrol-2-yl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-70-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1,3-benzodioxol-5-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-71-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(3-trifluoromethylphenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-72-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-,
(2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-73-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3,5-dichlorophenyl)methyl]-1,2,3,4,5,6-
hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-74-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(3-nitrophenyl)methyl]-
, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-75-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1R)-1-(3-bromophenyl)ethyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-76-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3,4-dichlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-77-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-fluorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-78-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 10-bromo-3-[(3-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-79-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-80-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-81-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-82-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(3-methoxyphenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-83-0 CAPLUS

CN Benzonitrile, 3-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-84-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(5-bromo-2-thienyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-85-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(2-methoxy-1-naphthalenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-86-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-87-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-(benzo[b]thien-2-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-88-5 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(4,5-dibromo-2-thienyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616886-89-6 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-
(9CI) (CA INDEX NAME)



RN 616886-90-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(5-methyl-2-thienyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-91-0 CAPLUS

CN Benzenamine, 3-[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-92-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-pyrrol-2-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-93-2 CAPLUS

CN Benzenemethanol, 2-bromo-4-[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-94-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(5-bromo-2-furanyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-95-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methylphenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-96-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(5-chloro-1H-indol-2-yl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-97-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methoxy-1-naphthalenyl)methyl]-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-98-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-5-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616886-99-8 CAPLUS

CN Phenol, 3-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-01-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-thienylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-02-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-4-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-03-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1R)-2,3-dihydro-6-methoxy-1H-inden-1-yl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-04-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1-phenylethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-05-9 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(1R)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-06-0 CAPLUS


CN 2,5-Ethano-3-benzazocin-9-amine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 616887-07-1 CAPLUS


CN Benzenamine, 2-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-08-2 CAPLUS


CN 2,5-Ethano-3-benzazocin-7-amine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 616887-09-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1,2,3,4-tetrahydro-1-methyl-6-quinolinyl)methyl]-, (2S,5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-10-6 CAPLUS

CN Phenol, 4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-11-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(5-methyl-2-furanyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-12-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-([1,1'-biphenyl]-3-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-13-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(6-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-14-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-(1H-benzimidazol-2-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-15-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(7-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-16-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4-isooquinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-18-4 CAPLUS

CN Benzenemethanamine, 2-bromo-4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-19-5 CAPLUS

CN Phenol, 2-methoxy-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-20-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-phenylethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-21-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(2-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-
(2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-22-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1R)-1,2,3,4-tetrahydro-
1-naphthalenyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-23-1 CAPLUS

CN 1(2H)-Isoquinolinone, 3-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-
benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-24-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-nitrophenyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-25-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(8-quinolinyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-26-4 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(3-furanyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-27-5 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-7-nitro- (9CI) (CA INDEX NAME)



RN 616887-28-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-29-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 9-bromo-3-[(3-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-30-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-31-1 CAPLUS

CN Pyrrolidine, 1-benzoyl-3-phenyl-3-[2-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]ethyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-32-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1-methyl-1H-pyrrol-2-yl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-33-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1-phenyl-1H-pyrazol-4-yl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-34-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(2-chloro-3-quinoliny) methyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-35-5 CAPLUS

CN Benzonitrile, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-36-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1-methyl-1H-pyrazol-4-yl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-37-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(5-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-38-8 CAPLUS

CN Benzenamine, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-39-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-phenylpropyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-40-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(5-phenylpentyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-41-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-pyrazol-3-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-42-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-(2-furanyl methyl)-1,2,3,4,5,6-hexahydro-,
(2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-43-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4-phenylbutyl)-,
(2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-44-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-45-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methyl-1H-imidazol-2-yl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-46-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4-phenylbutyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-47-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-48-0 CAPLUS

CN Benzenemethanol, 4-[[*(2S,5R)*-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-49-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-phenylethyl)-, (*2R,5S*) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-50-4 CAPLUS

CN Benzoic acid, 2-bromo-4-[[*(2S,5R)*-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl] -, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-51-5 CAPLUS


CN 2(1H)-Quinolinone, 3-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-52-6 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-9-nitro- (9CI) (CA INDEX NAME)



RN 616887-53-7 CAPLUS


CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1-isouquinolinylmethyl)-, (2S,5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 616887-54-8 CAPLUS
 CN Pyrrolidine, 3-phenyl-1-(phenylsulfonyl)-3-[2-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 616887-55-9 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(8-methoxy-2-quinolinyl)methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 616887-56-0 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-pyridinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-57-1 CAPLUS
 CN Acetamide, N-[3-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-58-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4-quinolinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-59-3 CAPLUS

CN Benzoic acid, 4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-60-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4-pyridinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-61-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(5-phenylpentyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-62-8 CAPLUS

CN Benzenemethanamine, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-63-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-phenylpropyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-64-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-naphthalenylmethyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-65-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[[5-(methoxymethyl)-2-furanyl]methyl]-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-66-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-67-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(2-pyridinylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-68-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-hexyl-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-69-5 CAPLUS

CN 1H-Pyrrole-2,4-dicarboxylic acid, 3-methyl-5-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-70-8 CAPLUS

CN 4-Morpholineethanamine, N-[[2-bromo-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]phenyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-71-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-hexyl-1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-72-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-nonyl-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-73-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(5-methylhexyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-74-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1-oxo-4-phenylbutyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-75-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-76-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(2-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-
(2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-77-5 CAPLUS


CN 4-Morpholineethanamine, N-[[4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-78-6 CAPLUS


CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-3-(phenylacetyl)-
(9CI) (CA INDEX NAME)



RN 616887-79-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-80-0 CAPLUS

CN Phenol, 4-[[[(2R,5S)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-81-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methylphenyl)methyl]-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-82-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-ethyl-1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 616887-83-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-84-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-pyrazol-4-ylmethyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-85-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(5-chloro-1H-indol-2-yl)carbonyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-86-6 CAPLUS


CN Benzoic acid, 2-bromo-4-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616887-87-7 CAPLUS


CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 616887-88-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-(2-benzothiazolylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-89-9 CAPLUS

CN Benzenemethanesulfonamide, 2-chloro-4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-90-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-butyl-1,2,3,4,5,6-hexahydro-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-91-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(3-methylbutyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-92-4 CAPLUS

CN Benzoic acid, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-93-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4,4,4-trifluorobutyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-94-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(4,4,4-trifluorobutyl)-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-95-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1S)-1-(3-bromophenyl)ethyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-96-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1S)-2,3-dihydro-6-methoxy-1H-inden-1-yl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-97-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(1S)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616887-99-1 CAPLUS

CN Pyrrolidine, 3-phenyl-1-(phenylsulfonyl)-3-[2-[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]ethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616888-00-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[1-(3-bromophenyl)ethyl]-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 616888-03-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, hydrochloride, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 616888-04-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-indol-2-ylmethyl)-, monohydrochloride, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 616888-14-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616888-22-3 CAPLUS


CN 2,5-Ethano-3-benzazocine, 3-[(4-bromo-1H-pyrrol-2-yl)methyl]-1,2,3,4,5,6-

hexahydro-, (2S,5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 616886-69-2
CMF C18 H21 Br N2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616888-23-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-(1H-pyrrol-2-ylmethyl)-, (2S,5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 616886-92-1
CMF C18 H22 N2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 616888-46-1 CAPLUS
CN Benzoic acid, 4-[[[(2S,5R)-1,4,5,6-tetrahydro-2,5-ethano-3-benzazocin-3(2H)-yl]methyl]-, 2-(4-morpholinyl)ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 616887-92-4
CMF C27 H34 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 616887-98-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(reactant; preparation of hexahydro(epiminomethano)benzo[a] [8]annulene
derivs. as tyrosine kinase inhibitors for treatment of receptor type
tyrosine kinase-related diseases)

RN 616887-98-0 CAPLUS

CN Pyrrolidine, 1-benzoyl-3-phenyl-3-[2-[(2S,5R)-1,4,5,6-tetrahydro-2,5-
ethano-3-benzazocin-3(2H)-yl]ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 616888-08-5 616888-30-3 616888-31-4


616888-36-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of hexahydro(epiminomethano)benzo[a] [8]annulene
derivs. as tyrosine kinase inhibitors for treatment of receptor type
tyrosine kinase-related diseases)

RN 616888-08-5 CAPLUS


CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-10-nitro- (9CI) (CA
INDEX NAME)



RN 616888-30-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 9-bromo-1,2,3,4,5,6-hexahydro-, hydrobromide,
(2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 616888-31-4 CAPLUS


CN 2,5-Ethano-3-benzazocine, 9-bromo-1,2,3,4,5,6-hexahydro-, (2S,5R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 616888-36-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-[2-(3-phenyl-3-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 83090-54-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reactant; preparation of hexahydro(epiminomethano)benzo[a][8]annulene derivs. as tyrosine kinase inhibitors for treatment of receptor type tyrosine kinase-related diseases)

RN 83090-54-4 CAPLUS


CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX)

NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



Q= —(CR¹?₂)_n-X-(CR¹?₂)_p-V-(R²)_q

AB The present invention relates to benzazocine compds. [I; wherein R = H, OR₄, each (un)substituted C₁-10 alkyl, aryl, C₃-10 cycloalkyl, or heterocyclyl, -C(O)R₄, C(O)OR₄, CON(R₄)₂; R_{1a} = H, (un)substituted C₁-6 alkyl, OR₄; R_{1b} = H, (un)substituted C₁-6 alkyl; X = a bond, CO, O, NR₄; R₁ = H, halo, OR₄, NO₂, S(O)mR₄, cyano, each (un)substituted C₁-10 alkyl, aryl, C₂-6 alkenyl, C₃-10 cycloalkyl, alkynyl, or heterocyclyl, COR₄, CO₂R₄, CON(R₄)₂, S(O)mN(R₄)₂, N(R₄)₂; V = H, CF₃, aryl, heterocyclyl, C₃-10 cycloalkyl; R₂ = H, (un)substituted C₁-10 alkyl, (CR_{1b})tOR₄, halo, cyano, NO₂, CF₃, (CR_{1b})tN(R₄)₂, CO₂R₄, COR₄, SO₂R₄, (CR_{1b})tNR₄(CR_{1b})tR₅, (CR_{1b})tS(O)mNR₄, CO₂R₄, NR₄COR₄, each (un)substituted aryl or heterocyclyl; R₄ = H, each (un)substituted C₁-10 alkyl, C₃-10 cycloalkyl, aryl, or heterocyclyl, CF₃; R₅ = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n = 0 to 6; p, q = 0 to 6; provided that when V is H or CF₃, q is 0; p₁, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase, in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.

AN 2003:836789 CAPLUS

DN 139:337898

TI Preparation of 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[a] [8]annulene derivatives as tyrosine kinase inhibitors

IN Kim, Annette

PA Merck & Co., Inc., USA


SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086314	A2	20031023	WO 2003-US12456	20030408
	WO 2003086314	A3	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480754	AA	20031023	CA 2003-2480754	20030408
	AU 2003231747	A1	20031027	AU 2003-231747	20030408
	EP 1496898	A2	20050119	EP 2003-746762	20030408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527580	T2	20050915	JP 2003-583339	20030408
	US 2006167036	A1	20060727	US 2004-510609	20041008
PRAI	US 2002-372358P	P	20020412		
	WO 2003-US12456	W	20030408		
OS	MARPAT 139:337898				
IT	615561-23-4P 615561-26-7P 615561-29-0P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of hydro(epiminomethano)benzo[a] [8]annulene derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)				
RN	615561-23-4 CAPLUS				
CN	2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-4-oxo-, 1,1-dimethylethyl ester, (2R,5S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 615561-26-7 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-4-methoxy-, 1,1-dimethylethyl ester, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615561-29-0 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-, oxime (9CI) (CA INDEX NAME)



IT 615560-81-1P 615560-82-2P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of hydro(epiminomethano)benzo[a][8]annulene derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)
 RN 615560-81-1 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, hydrochloride, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 615560-82-2 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, hydrochloride, (2S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 615560-79-7P 615560-80-0P 615560-83-3P
 615560-84-4P 615560-85-5P 615560-86-6P
 615560-87-7P 615560-88-8P 615560-89-9P
 615560-90-2P 615560-91-3P 615560-92-4P
 615560-93-5P 615560-94-6P 615560-95-7P
 615560-96-8P 615560-97-9P 615560-98-0P
 615560-99-1P 615561-00-7P 615561-01-8P
 615561-02-9P 615561-03-0P 615561-04-1P
 615561-05-2P 615561-06-3P 615561-07-4P
 615561-08-5P 615561-09-6P 615561-10-9P
 615561-11-0P 615561-12-1P 615561-14-3P
 615561-16-5P 615561-18-7P 615561-20-1P
 615561-22-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydro(epiminomethano)benzo[a][8]annulene derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615560-79-7 CAPLUS


CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, (2R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615560-80-0 CAPLUS


CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 615560-83-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, (2S,4S,5R)- (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-84-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-85-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-phenyl-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-86-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(phenylmethyl)-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-87-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(phenylmethyl)-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-88-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(phenylmethyl)-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-89-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(phenylmethyl)-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-90-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-91-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-92-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-93-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-94-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-95-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-96-8 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-97-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-98-0 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615560-99-1 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-00-7 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-01-8 CAPLUS

CN 2,5-Ethano-3-benzazocin-10-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-02-9 CAPLUS

CN 2,5-Ethano-3-benzazocin-7-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-03-0 CAPLUS

CN 2,5-Ethano-3-benzazocin-7-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-04-1 CAPLUS

CN 2,5-Ethano-3-benzazocin-7-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-05-2 CAPLUS

CN 2,5-Ethano-3-benzazocin-7-amine, 4-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-06-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(2-benzofuranyl methyl)-1,2,3,4,5,6-hexahydro-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-07-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(2-benzofuranyl methyl)-1,2,3,4,5,6-hexahydro-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-08-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(2-benzofuranyl methyl)-1,2,3,4,5,6-hexahydro-,
(2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-09-6 CAPLUS

CN 2,5-Ethano-3-benzazocine, 4-(2-benzofuranyl methyl)-1,2,3,4,5,6-hexahydro-,
(2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-10-9 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(2-oxazolyl methyl)-,
(2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-11-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(2-oxazolylmethyl)-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-12-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(2-oxazolylmethyl)-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-14-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(2-oxazolylmethyl)-, (2R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-16-5 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(3-methylbutyl)-, (2S,4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-18-7 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(3-methylbutyl)-, (2S,4R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-20-1 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(3-methylbutyl)-, (2R,4S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615561-22-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-4-(3-methylbutyl)-, (2R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 615561-24-5 615561-30-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of hydro(epiminomethano)benzo[a] [8]annulene derivs.
as tyrosine kinase inhibitors for treating receptor type tyrosine
kinase-related disorders)

RN 615561-24-5 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-, (2R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 615561-30-3 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-, (2S,5R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.





IT 129177-71-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(reactant; preparation of hydro(epiminomethano)benzo[a][8]annulene derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 129177-71-5 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI

I




II


AB Triazoles I [R1 = (un)substituted adamantyl; W = (un)substituted NH, bond; X = CH₂, bond; Z = S, bond; R2 = H, (un)substituted alkyl, alkenyl, CH₂CO₂H, cycloalkyl, bicycloalkyl, adamantyl; R3 = H, (un)substituted alkyl, alkenyl] were prepared. They inhibit the 11 β -HSD1-mediated conversion of cortisone and other 11-keto-glucocorticoids to cortisol and other 11 β -hydroxy-glucocorticoids (no data). The 11 β -HSD1 inhibitors therefore decrease the amount of cortisol in target tissues, thereby modulating the effects of cortisol. Modulation of cortisol may be effective in controlling non-insulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM or with excess cortisol in the body. Thus, the triazole II was prepared by treating 1-adamantanecarbonylhydrazine with 2-methoxy-5,5-dimethyl-3,4,5,6-tetrahydropyridine-6-acetonitrile.

AN 2003:633402 CAPLUS

DN 139:180065
 TI Preparation of 1,2,4-triazole derivatives as 11 β -hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
 IN Balkovec, James M.; Thieringer, Rolf; Mundt, Steven S.; Hermanowski-Vosatka, Anne; Graham, Donald W.; Patel, Gool F.; Aster, Susan D.; Waddell, Sherman T.; Olson, Steven H.; Maletic, Milana
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003065983	A2	20030814	WO 2003-US2558	20030128
	WO 2003065983	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474168	AA	20030814	CA 2003-2474168	20030128
	AU 2003207717	A1	20030902	AU 2003-207717	20030128
	EP 1474139	A2	20041110	EP 2003-705952	20030128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005525326	T2	20050825	JP 2003-565409	20030128
	US 2005070720	A1	20050331	US 2004-502967	20040729
PRAI	US 2002-353592P	P	20020201		
	WO 2003-US2558	W	20030128		
OS	MARPAT 139:180065				
IT	83090-60-2				
	RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of 1,2,4-triazole derivs. as 11 β -hydroxysteroid dehydrogenase 1 inhibitors)				
RN	83090-60-2 CAPLUS				
CN	2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8-methoxy- (9CI) (CA INDEX NAME)				





AB Hexahydromethanobenzocyclooctenone I ($X = O$) was prepared by condensation of α -xylene- α, α' -diyl dibromide with N-cyclopentylidene pyrrolidine and converted by Beckmann rearrangement of I ($X = NOH$) into tetrahydroethanobenzazocinone II ($R = H$). 2,3-Bis(bromomethyl)benzo[b]thiophene was converted similarly into a mixture of tetrahydroethanobenzothienoazocinones III ($X_1 = NH$, $X_2 = CO$; $X_1 = CO$, $X_2 = NH$). II ($R = H$) was N-methylated and II ($R = H$, Me) were reduced with $LiAlH_4$ to the saturated products. Conversion of II ($R = H$) into the corresponding thiolactam with P2S5 followed by alkylation gave an N- or S-alkylated derivative, (e.g., IV, $R = Me$, Et), depending on the reagent and reaction conditions. The structures of a number of compds. in this work are based on the x-ray anal. of III ($X_1 = CO$, $X_2 = NMe$).

AN 1990:531976 CAPLUS

DN 113:131976

TI Synthesis and reactions of 2,3,5,6-tetrahydro-2,5-ethano-3-benzazocin-4(1H)-one and a thieno-extended analog: x-ray structure of 3-methyl-2,3,5,6-tetrahydro-2,5-ethano[1]benzothieno[3,2-d]azocin-4(1H)-one

AU Iddon, Brian; Redhouse, Alan D.; Yat, Patrick N.

CS Dep. Chem. Appl. Chem. Univ. Salford. Salford. M5 4WT. UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1990). (4). 1083-90

CODEN: JCPRB4: ISSN: 0300-922X

DT Journal

LA English


OS CASREACT 113:131976

IT 129177-79-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 129177-79-3 CAPIUS


CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




IT 129177-80-6P 129177-84-0P 129177-90-8P
 129177-92-0P 129177-93-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 129177-80-6 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-methyl- (9CI) (CA INDEX
 NAME)




RN 129177-84-0 CAPLUS
 CN 2,5-Ethano-3-benzazocine-4(1H)-thione, 2,3,5,6-tetrahydro-3-methyl- (9CI)
 (CA INDEX NAME)



RN 129177-90-8 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




RN 129177-92-0 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI) (CA
 INDEX NAME)




● HCl


RN 129177-93-1 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-,
 (1,2,5,6-tetrahydro-2,5-ethano-3-benzazocin-4-yl)hydrazone (9CI) (CA
 INDEX NAME)




IT 129177-81-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, ethylation and methylation of)
 RN 129177-81-7 CAPLUS
 CN 2,5-Ethano-3-benzazocine-4(1H)-thione, 2,3,5,6-tetrahydro- (9CI) (CA INDEX NAME)



IT 129177-71-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, methylation, reduction and sulfurization of)
 RN 129177-71-5 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro- (9CI) (CA INDEX NAME)




L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 GI



AB Isomers of hexahydroethanobenzazocine I (R = H, R1 = OH, R = OH, R1 = H) were prepared via Beckmann rearrangement of syn- and anti-oximes II. Because of the similarity in their IR, NMR, and mass spectra, it was impossible to distinguish between the different isomers. Selective benzylic oxidation and NMR shift reagent studies gave results that determined the structures.
 AN 1983:612411 CAPLUS
 DN 99:212411
 TI Preparation and stereochemistry of 8- and 9-hydroxy-2,5-ethano-3-


benzazocines

AU Belanger, Patrice C.; Scheigetz, John; Young, Robert N.
 CS Med. Chem. Dep., Merck Frosst Canada Inc., Pointe-Claire/Dorval, QC, H9R
 4P8, Can.
 SO Canadian Journal of Chemistry (1983), 61(9), 2177-82
 CODEN: CJCHAG; ISSN: 0008-4042
 DT Journal
 LA English
 OS CASREACT 99:212411
 IT 87850-51-9P 87850-55-3P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and NMR of)
 RN 87850-51-9 CAPLUS
 CN 2,5-Ethano-3-benzazocin-1(2H)-one, 3,4,5,6-tetrahydro-8-methoxy-3-methyl-
 (9CI) (CA INDEX NAME)




Sauer m
 433 2810
 us


RN 87850-55-3 CAPLUS
 CN 2,5-Ethano-3-benzazocin-6(1H)-one, 2,3,4,5-tetrahydro-9-methoxy-3-methyl-
 (9CI) (CA INDEX NAME)




IT 83090-54-4P 83090-57-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and acylation of, by chloroformate)
 RN 83090-54-4 CAPLUS
 CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX
 NAME)




RN 83090-57-7 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX
 NAME)




IT 83090-48-6P 83090-50-0P 87850-49-5P
 87850-53-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydride reduction of)
 RN 83090-48-6 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-hydroxy- (9CI)
 (CA INDEX NAME)




RN 83090-50-0 CAPLUS
 CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8-hydroxy- (9CI)
 (CA INDEX NAME)




RN 87850-49-5 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-8-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 87850-53-1 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-9-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




IT 87850-48-4P 87850-52-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and methylation of)
 RN 87850-48-4 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-8-
 hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 87850-52-0 CAPLUS
 CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-9-
 hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



IT 87850-50-8P 87850-54-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidation of)
 RN 87850-50-8 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-methyl- (9CI)
 (CA INDEX NAME)




RN 87850-54-2 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-methoxy-3-methyl- (9CI)
 (CA INDEX NAME)




IT 83090-49-7P 87850-47-3P 87864-71-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and saponification of)


RN 83090-49-7 CAPLUS
CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-[(4-methylphenyl)sulfonyloxy]- (9CI) (CA INDEX NAME)




RN 87850-47-3 CAPLUS
CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8-[(4-methylphenyl)sulfonyloxy]- (9CI) (CA INDEX NAME)



RN 87864-71-9 CAPLUS
CN 2,5-Ethano-3-benzazocine-3(2H)-carboxylic acid, 8-[(ethoxycarbonyl)oxy]-1,4,5,6-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




IT 83090-51-1P 83090-52-2P 87850-56-4P
87850-57-5P 87850-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 83090-51-1 CAPLUS
CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 83090-52-2 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 87850-56-4 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 87850-57-5 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-methoxy-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 87850-58-6 CAPLUS
 CN 2,5-Ethano-3-benzazocin-6(1H)-one, 2,3,4,5-tetrahydro-9-methoxy-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 GI



AB Title compds. I and II (R and R1 independently are H, alkyl; R2 = alkyl, alkenyl, cycloalkylmethyl, phenylalkyl; R3 = H, Me), useful as analgesics (no data), were prepared. The syn-oxime of 11-oxo-2-hydroxy-6,9-methano-5,6,7,8,9,10-hexahydrobenzocyclooctene was treated with tosyl chloride to give 2,5-ethano-8-hydroxy-4-oxo-1,2,3,4,5,6-hexahydro-3-benzazocine, the latter was reduced (LiAlH4), and the product was treated with 4-ClC6H4CHO and NaB(CN)H3 to give I (R2 = 4-ClC6H4CH2, R = R1 = R3 = H).

AN 1982:544795 CAPLUS

DN 97:144795

TI N-(Substituted)-2,5-ethano-8-hydroxy (or methoxy)-1,2,3,4,5,6-hexahydro-3 (or 4)-benzazocine centrally-acting analgesics

IN Belanger, Patrice C.; Young, Robert N.

PA Merck and Co., Inc., USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4332810	A	19820601	US 1981-228483	19810126
	CA 1184907	A1	19850402	CA 1982-394863	19820125

PRAI US 1981-228483 A 19810126


OS MARPAT 97:144795

IT 83090-49-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and detosylation of)

RN 83090-49-7 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-[(4-methylphenyl)sulfonyl]oxy- (9CI) (CA INDEX NAME)




IT 83090-48-6P 83090-50-0P 83090-59-9P

83090-60-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydride reduction of)


RN 83090-48-6 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-hydroxy- (9CI)
(CA INDEX NAME)




RN 83090-50-0 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8-hydroxy- (9CI)
(CA INDEX NAME)




RN 83090-59-9 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-9-methoxy- (9CI)
(CA INDEX NAME)



RN 83090-60-2 CAPLUS

CN 2,5-Ethano-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8-methoxy- (9CI)
(CA INDEX NAME)




IT 83090-54-4P 83090-57-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reductive N-alkylation of, by benzaldehydes)

RN 83090-54-4 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX
NAME)

RN 83090-57-7 CAPLUS


CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX
NAME)

IT 83090-54-4P 83090-61-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and N-alkylation of, by chlorobenzyl chloride)

RN 83090-54-4 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX
NAME)

RN 83090-61-3 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy- (9CI) (CA
INDEX NAME)

IT 83090-41-9P 83090-42-0P 83090-43-1P

83090-44-2P 83090-51-1P 83090-52-2P

83090-53-3P 83090-55-5P 83090-56-6P

83090-58-8P 83090-62-4P 83090-63-5P

83090-64-6P 83090-65-7P 83090-66-8P


83090-67-9P 83090-68-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 83090-41-9 CAPLUS

CN Benzenamine, N,N-dimethyl-4-[(1,4,5,6-tetrahydro-8-methoxy-2,5-ethano-3-benzazocin-3(2H)-yl)methyl] - (9CI) (CA INDEX NAME)




RN 83090-42-0 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 83090-43-1 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 83090-44-2 CAPLUS

CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-9-methoxy-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 83090-51-1 CAPLUS

CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 83090-52-2 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-, hydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 83090-53-3 CAPLUS
 CN 2,5-Ethano-3-benzazocin-9-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 83090-55-5 CAPLUS
 CN 2,5-Ethano-3-benzazocin-9-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 83090-56-6 CAPLUS


CN 2,5-Ethano-3-benzazocin-8-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 83090-58-8 CAPLUS


CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 83090-62-4 CAPLUS

CN 2,5-Ethano-3-benzazocine, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 83090-63-5 CAPLUS

CN 2,5-Ethano-3-benzazocin-8-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




RN 83090-64-6 CAPLUS


CN 2,5-Ethano-3-benzazocin-9-ol, 3-[(4-chlorophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




RN 83090-65-7 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-[(4-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 83090-66-8 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 3-[(4-(dimethylamino)phenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 83090-67-9 CAPLUS
 CN 2,5-Ethano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 83090-68-0 CAPLUS
 CN 2,5-Ethano-3-benzazocine, 1,2,3,4,5,6-hexahydro-8-methoxy-3-[(4-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)



=> logoff y
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
33.88	368.43

01/12/2006

Page 101

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

STN INTERNATIONAL LOGOFF AT 17:02:41 ON 01 DEC 2006

10510609